比阿培南治疗慢性阻塞性肺疾病急性加重期临床评价

Clinical effects of Biapenem in patients with acute exacerbation of chronic obstructive pulmonary disease

目的探讨比阿培南治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)Anthonisen I型或需要有创或无创通气的患者的临床疗效及安全性。方法将68例患者分为2组:实验组32例应用比阿培南治疗,对照组36例用亚胺培南/西司他丁治疗,连续检测C-反应蛋白(C-reactive pro-tein,CRP)水平,比较2组临床疗效及细菌清除率,并了解其安全性。结果实验组:临床痊愈率为71.8%,临床有效率为90.6%,细菌清除率为90.9%;对照组:临床痊愈率为66.7%,临床有效率为86.1%,细菌清除率为78.3%;均未见严重不良反应。经治疗后CRP均下降明显,治疗第3天实验组25例CRP下降50%,对照组28例CRP下降50%,差异无统计学意义。结论比阿培南治疗AECOPD Anthonisen I型或需要有创或无创通气的患者感染疗效迅速、确切,副作用小。

Objective To observe the efficacy and safety of Biapenem in the treatment of Anthonisen I and mechanical ventilation will be demanded in acute exacerbation of chronic obstructive pulmonary disease（AECOPD） .Methods A control study of Biapenem （the treatment group） and imipenem-cilastatin （the control group） in the treatment of 68 pa-tients was carried out.The C-reactive protein levels were measured on admission,and on day 3 patients with a decline of50% in CRP levels in the two groups were compared.Results The total effective rates of Biapenem and imipenem-cilastatin were 90.6.3% and 86.1% and bacterial clearance rates were 90.3 and 78.3% ,respectively.An obvious de-crease of CRP level was found in 3 days,but patients with a decline of50% in CRP had no obvious difference between the two groups.Serious adverse effect was not seen.Conclusion Biapenem is effective and safe in treating patients with Anthonisen I and mechanical ventilation will be demanded in AECOPD and has good bacterial clearance rates.